- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Collexis' BiomedExperts Rapidly Expanding its User Base Giving Researchers and Publishers an Easy and Efficient Way to Network, Connect and Collaborate
Collexis Holdings Inc, (OTCBB: CLXS) a leading developer of high definition search and knowledge discovery software, announced today that its premier professional scientific social networking site, Biomedexperts.com, has more than 30,000 registered users, enabling researchers across organizations and around the globe to collaborate more efficiently and effectively.
In April Collexis implemented the first phase of their marketing campaign and since that time BiomedExperts' user registrations have skyrocketed from 2,000 to more than 30,000. BiomedExperts.com is a collaborative agreement with Dell Healthcare and Life Sciences. Through this initiative, Dell is providing the hardware and continued marketing support for the site and Collexis is contributing knowledge discovery and text mining applications.
"The success of BiomedExperts.com is a testament to the role innovative technology can play in enabling researchers to collaborate and drive meaningful scientific discoveries," said James Coffin, Ph.D., vice president and general manager, Dell Health Care and Life Sciences. "The possibilities are tremendous when scientists of varying disciplines work together on a similar goal, and in this connected era bringing research communities together through technology can have real and significant impact on scientific discoveries and ultimately patient care."
Pre-populated with over 1.5 million Pub-Med-based expert profiles, BiomedExperts allows scientists and researchers to directly connect with and explore their own professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. Through user-friendly search interfaces, potential research collaborators can share data and collaborate with professionals from more than 1,800 organizations and institutions from 137 countries, totaling more than 21 million connections made through the site.
"It's exciting to see how this tool is paving the way for researchers to grow their professional networks and connect with professionals in the scientific research community," said Bill Kirkland, CEO of Collexis Holdings, Inc. "And now, with more than 30,000 registered users, we hope the collaborative opportunities will continue to increase rapidly, furthering our mission to provide scientists and researchers with the tools they need to help advance medical science, thereby improving the greater good."
To learn more about Collexis and how BiomedExperts is improving research capabilities, please visit www.collexis.com and www.biomedexperts.com.
About Collexis Holdings Inc.
Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world’s first pre-populated scientific social network for life science researchers, <http://www.biomedexperts.com>www.biomedexperts.com. Collexis’ proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined “fingerprinted” concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as “finding needles in many haystacks.” Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis’ current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit <http://www.collexis.com>www.collexis.com.
Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company’s actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the development and enhancement of services provided through the BioMedExperts.com Web site. These risks and uncertainties are in addition to other factors detailed from time to time in the company’s filings with the SEC, including the section entitled “Risk Factors” in its transition report on Form 10-KSB for the period ended June 30, 2007, as amended. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.
For more information, please click here
Public Relations Specialist
1411 Gervais St., 5th Floor
Columbia, SC 29201
Copyright © Collexis Holdings, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Soft decoupling of organic molecules on metal June 23rd, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016